")}("position","absolute",["\/lib\/bootstrap\/dist\/css\/bootstrap.min.css"],"rel=\u0022stylesheet\u0022 ");
Published On: Saturday, May 9, 2020 | By: Team KnowMyStock
Earlier this year, Deshpande, hoping to get a response from Tata on his start-up model, wrote him an email. To his surprise, Tata already knew about the venture through his campaigns and he was called to his Mumbai office for a meeting. “During our meeting he said he wanted affordable and quality medicines to reach every Indian,” says the start-up founder. It took Deshpande four months and three meetings to seal a deal with Tata for his business.
The Tata Group chairman emeritus has now invested an undisclosed amount in the company and has suggested the start-up to focus on delivering cancer drugs at a reduced cost. “As happy as I am to support this venture, it has been a minority token investment. I have not purchased 50 percent stake in the company,” Tata tweeted Yesterday( 8th May 2020).
Follow Us On: